Clinical review: topical ophthalmic use of cyclosporin A.
about
Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplastyDry eye: an inflammatory ocular diseaseNovel formulations for antimicrobial peptidesWhat is causing the corneal ulcer? Management strategies for unresponsive corneal ulcerationInhibition of Pterygium Fibroblast Migration and Outgrowth by Bevacizumab and Cyclosporine A Involves Down-Regulation of Matrix Metalloproteinases-3 and -13Effects of immunosuppressants after penetrating keratoplasty: meta-analysis of randomized controlled trials.A single LipiFlow® Thermal Pulsation System treatment improves meibomian gland function and reduces dry eye symptoms for 9 months.Dry eye disease: A review of diagnostic approaches and treatmentsPreparation and evaluation of cyclosporin A-containing proliposomes: a comparison of the supercritical antisolvent process with the conventional film method.Functional and morphological analysis of the subretinal injection of human retinal progenitor cells under Cyclosporin A treatment.Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline.The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eyeOcular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit modelCharacterization and stability studies of a novel liposomal cyclosporin A prepared using the supercritical fluid method: comparison with the modified conventional Bangham methodDo Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells?Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up.Pharmacotherapy of corneal transplantation.Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface.The cellular mechanisms of dry eye: from pathogenesis to treatment.The role and treatment of inflammation in dry eye disease.Management of High-risk Corneal Transplantation.Systemic Immunomodulatory Strategies in High-risk Corneal Transplantation.Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.Therapeutical Management for Ocular Rosacea.Topical ophthalmic use of cyclosporin A for Splendore-Hoeppli phenomenon.In vivo confocal microscopic characterisation of the cornea in chronic graft-versus-host disease related severe dry eye disease.Corneal features in ocular graft-versus-host disease by in vivo confocal microscopy.Management of vernal keratoconjunctivitis.Immunotherapy for corneal inflammatory disorders: stepping up and down the ladder.Social-economic analysis of patients with Sjogren's syndrome dry eye in East China: a cross-sectional study.Vernal shield ulcers treated with frequently installed topical cyclosporine 0.05% eyedrops.The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren's syndrome.Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies.Advancements in Host-Based Interventions for Influenza Treatment
P2860
Q24187740-27CBB294-E145-4A17-8B46-804B2999CB34Q26852044-085C3DD3-E208-4029-B5F0-05A2D0C581DEQ26991771-4739F57E-DD38-46A8-8AD6-16D807976D03Q26995424-14755F21-A7C9-46ED-BBFA-6F8CF6B5F932Q28469505-D08D199E-6DE6-4609-A3C3-415E1E95D12AQ30467905-7C4FE8A8-74E4-4851-87A5-8DDA6791B6B5Q34253558-ED83660C-7E4B-4682-B65B-96F254A2EF79Q34273384-23F6250B-43C2-41EF-BB2C-34825F11F57AQ34471317-82FC4F00-1050-4F5B-8AC2-77A59303F348Q35373820-DD69701B-E3CD-41A7-AD42-68EDC80F1BA9Q35691929-6C33194F-AB43-4D21-AD8A-24E1C32FF4BAQ36039088-8E52BEB1-93F1-4A9C-8770-D3363CD0E9D3Q36182937-C57D167C-F2B7-4635-B108-758EF1FD7730Q36567529-8DA252E6-0B87-4728-985A-FC4BF0574B91Q37242107-089CBD6B-48D8-4C23-939C-6593E9A76EA2Q37471561-244965AD-8538-47A7-9067-31196402139FQ37994335-7B86F5A1-DD6E-40D5-B18B-20CD27C0FE97Q38040514-2093E372-7E37-4A63-AA34-95EA7050DF5FQ38108573-FF9A9680-4300-412F-95E7-87A75271A80BQ38270449-A90A6C6B-25D6-408C-949F-6F2821D419C9Q38778422-026CF142-E0EC-4306-858D-0575B4EB18ECQ38904800-B37A7945-E8F1-4C39-AEFD-B79D860CD7CAQ39730888-3CE10B38-0C1A-4FD8-807A-A7801717B4A3Q41951650-F4C2052A-A688-4BC8-AD14-CE61E07CF98AQ42257527-EEC2437D-2ACB-4169-8301-BF7AE245F49BQ42464221-0C7362A7-2FE5-4CCD-8B61-3DF94917B802Q42514475-2A6A4568-9F4F-43FB-86CA-FA9A249FC80AQ42745061-201A8696-805E-49FA-A2DE-755B4401AA1BQ44049378-E73F6E6E-57EF-47C0-9245-E5C201EF41C8Q47550026-507AE6EE-56D5-4566-BE1A-43F2A4C8B1BEQ48315235-ED8735D3-37A6-422E-A716-1488EA199E49Q50480678-B72C84CB-D09A-48B1-9D61-DA9F9CC71E1FQ52598288-7A7CC97E-14C7-4CFC-B923-29EDF37E0435Q56996774-B4982645-AE70-4B6C-9E4A-E054627416A4
P2860
Clinical review: topical ophthalmic use of cyclosporin A.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical review: topical ophthalmic use of cyclosporin A.
@en
Clinical review: topical ophthalmic use of cyclosporin A.
@nl
type
label
Clinical review: topical ophthalmic use of cyclosporin A.
@en
Clinical review: topical ophthalmic use of cyclosporin A.
@nl
prefLabel
Clinical review: topical ophthalmic use of cyclosporin A.
@en
Clinical review: topical ophthalmic use of cyclosporin A.
@nl
P2093
P2860
P1476
Clinical review: topical ophthalmic use of cyclosporin A.
@en
P2093
Canan Asli Utine
Esen K Akpek
Michael Stern
P2860
P304
P356
10.3109/09273948.2010.498657
P577
2010-10-01T00:00:00Z